Ana Sofia Rodrigues

Ana Sofia Rodrigues

Auto-generated profile, based on publicly available information

Ana Sofia Rodrigues

CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SVSandra Varum
Sandra Varum
ARAna S. Rodrigues
Ana S. Rodrigues
MMMichelle B. Moura
Michelle B. Moura
OMOlga Momcilovic
Olga Momcilovic
CECharles A. Easley
Charles A. Easley
GSGerald Schatten
Gerald Schatten
Human pluripotent stem cells have the ability to generate all cell types present in the adult organism, therefore harboring great potential for the in vitro study of differentiation and for the development of cell-based therapies. Nonetheless their use may prove challenging as incomplete differentiation of these cells might lead to tumoregenicity. Interestingly, many cancer types have been reported to display metabolic modifications with features that might be similar to stem cells. Understanding the metabolic properties of human pluripotent stem cells when compared to their differentiated counterparts can thus be of crucial importance. Furthermore recent data has stressed distinct features of different human pluripotent cells lines, namely when comparing embryo-derived human embryonic stem cells (hESCs) and induced pluripotent stem cells (IPSCs) reprogrammed from somatic cells. We compared the energy metabolism of hESCs, IPSCs, and their somatic counterparts. Focusing on mitochondria, we tracked organelle localization and morphology. Furthermore we performed gene expression analysis of several pathways related to the glucose metabolism, including glycolysis, the pentose phosphate pathway and the tricarboxylic acid (TCA) cycle. In addition we determined oxygen consumption rates (OCR) using a metabolic extracellular flux analyzer, as well as total intracellular ATP levels by high performance liquid chromatography (HPLC). Finally we explored the expression of key proteins involved in the regulation of glucose metabolism. Our results demonstrate that, although the metabolic signature of IPSCs is not identical to that of hESCs, nonetheless they cluster with hESCs rather than with their somatic counterparts. ATP levels, lactate production and OCR revealed that human pluripotent cells rely mostly on glycolysis to meet their energy demands. Furthermore, our work points to some of the strategies which human pluripotent stem cells may use to maintain high glycolytic rates, such as high levels of hexokinase II and inactive pyruvate dehydrogenase (PDH).


2 December 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPSandro L Pereira
Sandro L Pereira
Mário GrãosMário Grãos
Mário Grãos
ARAna Sofia Rodrigues
Ana Sofia Rodrigues
Sandra AnjoSandra Anjo
Sandra Anjo
RCRui A Carvalho
Rui A Carvalho
Joao Ramalho-SantosJoao Ramalho-Santos
Joao Ramalho-Santos
The mitochondrion is emerging as a key organelle in stem cell biology, acting as a regulator of stem cell pluripotency and differentiation. In this study we sought to understand the effect of mitochondrial complex III inhibition during neuronal differentiation of mouse embryonic stem cells. When exposed to antimycin A, a specific complex III inhibitor, embryonic stem cells failed to differentiate into dopaminergic neurons, maintaining high Oct4 levels even when subjected to a specific differentiation protocol. Mitochondrial inhibition affected distinct populations of cells present in culture, inducing cell loss in differentiated cells, but not inducing apoptosis in mouse embryonic stem cells. A reduction in overall proliferation rate was observed, corresponding to a slight arrest in S phase. Moreover, antimycin A treatment induced a consistent increase in HIF-1α protein levels. The present work demonstrates that mitochondrial metabolism is critical for neuronal differentiation and emphasizes that modulation of mitochondrial functions through pharmacological approaches can be useful in the context of controlling stem cell maintenance/differentiation.

1 April 2010 in Theriogenology
Verified
Journal Article
Closed access
SGS. Gamboa
S. Gamboa
ARA.S. Rodrigues
A.S. Rodrigues
LHL. Henriques
L. Henriques
CBC. Batista
C. Batista
Joao Ramalho-SantosJoao Ramalho-Santos
Joao Ramalho-Santos

1 January 2017 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
Marcelo CorreiaMarcelo Correia
Marcelo Correia
TPTânia Perestrelo
Tânia Perestrelo
ARAna S. Rodrigues
Ana S. Rodrigues
MRMarcelo F. Ribeiro
Marcelo F. Ribeiro
SPSandro L. Pereira
Sandro L. Pereira
Joao Ramalho-SantosJoao Ramalho-Santos
Joao Ramalho-Santos

6 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ARAna Sofia Rodrigues
Ana Sofia Rodrigues
Marcelo CorreiaMarcelo Correia
Marcelo Correia
AGAndreia Gomes
Andreia Gomes
SPSandro L Pereira
Sandro L Pereira
TPTânia Perestrelo
Tânia Perestrelo
Joao Ramalho-SantosJoao Ramalho-Santos
Joao Ramalho-Santos
The pyruvate dehydrogenase (PDH) complex is localized in the mitochondrial matrix catalyzing the irreversible decarboxylation of pyruvate to acetyl-CoA and NADH. For proper complex regulation the E1-α subunit functions as an on/off switch regulated by phosphorylation/dephosphorylation. In different cell types one of the four-pyruvate dehydrogenase kinase isoforms (PDHK1-4) can phosphorylate this subunit leading to PDH inactivation. Our previous results with human Embryonic Stem Cells (hESC), suggested that PDHK could be a key regulator in the metabolic profile of pluripotent cells, as it is upregulated in pluripotent stem cells. Therefore, we wondered if metabolic modulation, via inexpensive pharmacological inhibition of PDHK, could impact metabolism and pluripotency. In order to assess the importance of the PDH cycle in mouse Embryonic Stem Cells (mESC), we incubated cells with the PDHK inhibitor dichloroacetate (DCA) and observed that in its presence ESC started to differentiate. Changes in mitochondrial function and proliferation potential were also found and protein levels for PDH (both phosphorylated and non-phosphorylated) and PDHK1 were monitored. Interestingly, we were also able to describe a possible pathway that involves Hif-1α and p53 during DCA-induced loss of pluripotency. Results with ESCs treated with DCA were comparable to those obtained for cells grown without Leukemia Inhibitor Factor (LIF), used in this case as a positive control for differentiation. DCA negatively affects ESC pluripotency by changing cell metabolism and elements related to the PDH cycle, suggesting that PDHK could function as a possible metabolic gatekeeper in ESC, and may be a good target to modulate metabolism and differentiation. Although further molecular biology-based experiments are required, our data suggests that inactive PDH favors pluripotency and that ESC have similar strategies as cancer cells to maintain a glycolytic profile, by using some of the signaling pathways found in the latter cells.